Published in Biotech Business Week, March 15th, 2004
The trial demonstrated the use of TNFerade in combination with standard radiation therapy resulted in 21 of 30 patients experiencing tumor shrinkage of 25% or more, a 70% objective response rate across 12 different tumor types, as well as a positive safety profile.
The article is titled "TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter Carrying the Human Tumor Necrosis Factor Alpha Gene: A phase I...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.